About palivizuma b
Respiratory syncytial virus monoclonal antibody
Used for
- Prevents severe respiratory syncytial virus (RSV) disease in high-risk infants and young children.
Usual dose in children
15 mg/kg by muscle injection once monthly during RSV season; usually up to five doses.
Common side effects
- Fever
- Rash
- Injection-site reactions
Important warnings
- Not a treatment for active RSV infection.
- Severe allergic reactions can occur, including after previous doses.
- Use caution with bleeding disorders or low platelet counts.
Pregnancy
Not applicable for its approved use in infants and young children.
Breastfeeding
Not applicable for its approved use in infants and young children.
Interactions
- No clinically important interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.